Perth neurological drug developer Argenica Therapeutics says it has addressed several hurdles which led the US FDA to knock back clinical trials of its flagship ARG-007 stroke drug.

Perth neurological drug developer Argenica Therapeutics says it has addressed several hurdles which led the US FDA to knock back clinical trials of its flagship ARG-007 stroke drug.